NZ334268A - Controlled release dosage form of [R-(Z)]-alpha-(methoxyimino)-alpha-(1-azabicyclo [2.2.2]oct-3-yl) acetonitrile monohydrochloride - Google Patents

Controlled release dosage form of [R-(Z)]-alpha-(methoxyimino)-alpha-(1-azabicyclo [2.2.2]oct-3-yl) acetonitrile monohydrochloride

Info

Publication number
NZ334268A
NZ334268A NZ334268A NZ33426897A NZ334268A NZ 334268 A NZ334268 A NZ 334268A NZ 334268 A NZ334268 A NZ 334268A NZ 33426897 A NZ33426897 A NZ 33426897A NZ 334268 A NZ334268 A NZ 334268A
Authority
NZ
New Zealand
Prior art keywords
alpha
methoxyimino
azabicyclo
oct
dosage form
Prior art date
Application number
NZ334268A
Inventor
Susan Marie Milosovich
William Muldoon
James Albert Napper
Laurence Rousseau
Joseph Sauer
Original Assignee
Smithkline Beecham Corp
Smithkline Beecham P
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Smithkline Beecham Corp, Smithkline Beecham P filed Critical Smithkline Beecham Corp
Publication of NZ334268A publication Critical patent/NZ334268A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/439—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5073—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings
    • A61K9/5078—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings with drug-free core
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Abstract

The specification describes a controlled release oral dosage form containing [R-(Z)]-alpha-(methoxyimino)-alpha-(1-azabicyclo [2.2.2]oct-3-yl) acetonitrile monohydrochloride (compound X) and its use in the treatment and/or prophylaxis of dimentia. The above compound is reported to enhance acetylcholine function via an an action at muscarinic receptors within the CNS
NZ334268A 1996-09-12 1997-09-08 Controlled release dosage form of [R-(Z)]-alpha-(methoxyimino)-alpha-(1-azabicyclo [2.2.2]oct-3-yl) acetonitrile monohydrochloride NZ334268A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB9619074.9A GB9619074D0 (en) 1996-09-12 1996-09-12 Composition
PCT/GB1997/002418 WO1998010762A2 (en) 1996-09-12 1997-09-08 Controlled release dosage form of r-(z)-alpha-methoxyimino-alpha-(1-azabicyclo2.2oct-c-yl)acetonitrile monohydrochloride

Publications (1)

Publication Number Publication Date
NZ334268A true NZ334268A (en) 2000-10-27

Family

ID=10799833

Family Applications (1)

Application Number Title Priority Date Filing Date
NZ334268A NZ334268A (en) 1996-09-12 1997-09-08 Controlled release dosage form of [R-(Z)]-alpha-(methoxyimino)-alpha-(1-azabicyclo [2.2.2]oct-3-yl) acetonitrile monohydrochloride

Country Status (22)

Country Link
EP (1) EP0929301A2 (en)
JP (1) JP2001500150A (en)
KR (1) KR20000036039A (en)
CN (2) CN1235544A (en)
AR (1) AR008176A1 (en)
AU (1) AU724086B2 (en)
BR (1) BR9711734A (en)
CA (1) CA2265661A1 (en)
CO (1) CO5031291A1 (en)
CZ (1) CZ83299A3 (en)
GB (1) GB9619074D0 (en)
HU (1) HUP9904401A3 (en)
ID (1) ID19589A (en)
IL (1) IL128781A0 (en)
MA (1) MA24359A1 (en)
NO (1) NO991194L (en)
NZ (1) NZ334268A (en)
PE (1) PE2499A1 (en)
PL (1) PL332074A1 (en)
TR (1) TR199900505T2 (en)
WO (1) WO1998010762A2 (en)
ZA (1) ZA978133B (en)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2775597B1 (en) * 1998-03-04 2001-04-20 Gattefosse Ets Sa ORAL PELLET ADAPTED TO IMPROVE THE BIOAVAILABILITY OF THE ACTIVE SUBSTANCE, METHOD OF MANUFACTURE
KR20010034588A (en) * 1998-03-11 2001-04-25 피터 기딩스 Composition
DE19918325A1 (en) * 1999-04-22 2000-10-26 Euro Celtique Sa Extruded drug dosage form, e.g. granulate for tableting, comprising an active agent in a polysaccharide-containing matrix, giving a release profile which is controllable by extrusion conditions and/or the inclusion of additives
FR2796840B1 (en) 1999-07-26 2003-06-20 Ethypharm Lab Prod Ethiques LOW-DOSE TABLETS AND METHOD OF PREPARATION
US6733781B2 (en) 2000-12-06 2004-05-11 Wyeth Fast dissolving tablet
AR040682A1 (en) 2002-07-25 2005-04-13 Pharmacia Corp DOSAGE FORM ONCE A DAY OF PRAMIPEXOL
JP4808612B2 (en) * 2003-04-25 2011-11-02 田辺三菱製薬株式会社 Composition for oral administration containing alkylenedioxybenzene derivative
ES2273271T5 (en) * 2003-05-14 2013-05-21 Aptalis Pharma Limited Composition of controlled release of mechanical stress resistant drug in vivo
US20050142191A1 (en) * 2003-06-23 2005-06-30 Neurochem (International) Limited Pharmaceutical formulations of amyloid inhibiting compounds
JP2005272347A (en) * 2004-03-24 2005-10-06 Ohara Yakuhin Kogyo Kk Method for producing solid preparation
EA200700388A1 (en) * 2004-08-13 2007-08-31 Бёрингер Ингельхайм Интернациональ Гмбх THE COMPOSITION OF PELLETS OF THE PROLONGED SURVENT, CONTAINING PRAMIPEXOL OR ITS PHARMACEUTICALLY ACCEPTABLE SALT, THE WAY OF ITS MANUFACTURE AND ITS APPLICATION
CN101884626A (en) 2004-08-13 2010-11-17 贝林格尔.英格海姆国际有限公司 The prolongation release tablet, the Preparation Method And The Use that comprise pramipexole or its officinal salt
EP1970056A1 (en) * 2007-03-15 2008-09-17 Polichem S.A. Time-specific delayed/pulsatile release dosage forms
US9132096B1 (en) 2014-09-12 2015-09-15 Alkermes Pharma Ireland Limited Abuse resistant pharmaceutical compositions

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK0392803T3 (en) * 1989-04-13 2004-10-18 Beecham Group Plc Hitherto unknown compounds
GB9409718D0 (en) * 1994-05-14 1994-07-06 Smithkline Beecham Plc Novel compounds
GB9421472D0 (en) * 1994-10-25 1994-12-07 Smithkline Beecham Plc Novel methods
AR004178A1 (en) * 1995-07-29 1998-11-04 Smithkline Beecham Plc PROCEDURE FOR THE FORMULATION OF A PHARMACY, A PHARMACEUTICAL COMPOSITION OBTAINABLE THROUGH THIS PROCEDURE AND THE USE OF THE SAME.

Also Published As

Publication number Publication date
NO991194D0 (en) 1999-03-11
JP2001500150A (en) 2001-01-09
PL332074A1 (en) 1999-08-30
GB9619074D0 (en) 1996-10-23
PE2499A1 (en) 1999-03-24
HUP9904401A3 (en) 2001-03-28
ID19589A (en) 1998-07-23
NO991194L (en) 1999-03-11
CO5031291A1 (en) 2001-04-27
WO1998010762A2 (en) 1998-03-19
TR199900505T2 (en) 1999-06-21
WO1998010762A3 (en) 1998-06-04
ZA978133B (en) 1999-04-12
AU724086B2 (en) 2000-09-14
HUP9904401A2 (en) 2000-06-28
IL128781A0 (en) 2000-01-31
CN1235544A (en) 1999-11-17
MA24359A1 (en) 1998-07-01
CA2265661A1 (en) 1998-03-19
CZ83299A3 (en) 1999-08-11
KR20000036039A (en) 2000-06-26
AR008176A1 (en) 1999-12-09
AU4128897A (en) 1998-04-02
EP0929301A2 (en) 1999-07-21
CN1446535A (en) 2003-10-08
BR9711734A (en) 1999-08-24

Similar Documents

Publication Publication Date Title
NZ334268A (en) Controlled release dosage form of [R-(Z)]-alpha-(methoxyimino)-alpha-(1-azabicyclo [2.2.2]oct-3-yl) acetonitrile monohydrochloride
GB2206788B (en) 5 ht-3 antagonist for the treatment or reduction of dependence
EP0605024A3 (en) Use of purified surface modifiers to prevent particle aggregation during sterilization.
GR3022031T3 (en) Pharmacologically active CNS compounds
EG19511A (en) Formation of high active detergent particles
HUP0101043A3 (en) Controlled release oral dosage form containing [r-(z)]-alpha-(methoxyimino)-alpha-(1-azabicyclo[2.2.2]oct-3-yl]acetonitrile monohydrochlorid and process for its preparation
TW414158U (en) Construction of structural body
NZ232946A (en) Preparation of crystalline 17alpha-hydroxy-7alpha methyl-19-nor-17-pregn-5
AU1916192A (en) Use of sigma receptor antagonists to enhance the effects of antipsychotic drugs
AU1461892A (en) Use of sigma receptor antagonists for treatment of cocaine abuse
AU1583492A (en) Use of sigma receptor antagonists for treatment of amphetamine abuse
ZA886247B (en) Use of a compound for the treatment of schizophrenia
HU896122D0 (en) Process for the formation of active agents for waxed tablets
AU2884489A (en) Compounds with a psychotropic action, agents containing them, and the use thereof for the treatment and prophylaxis of disorders of the central nervous system
HU905990D0 (en) Cleaner containing amino-phosphates as active agent and process for producing these compounds
TR199900141T2 (en) Formulation for the treatment and/or prophylaxis of dementia.
GB9222012D0 (en) Improvements relating to the treatment of haemophilia
GB9815383D0 (en) Novel method of treatment
AU1455395A (en) Use of m3 muscarinic antagonists for the treatment of motion sickness
GB2240476B (en) 5 ht-3 antagonists for the prevention or reduction of dependence
GB8730192D0 (en) Pharmacologically active compounds & use
HU901306D0 (en) Sprinkler body for managing to pass artificital fetilizer out
RO105585B1 (en) Medicinal composition used in the treatment of shank's ulcer
HU9300520D0 (en) Game of chance named "where is the ball?"
ZA899327B (en) Pharmaceutically active cns compounds

Legal Events

Date Code Title Description
RENW Renewal (renewal fees accepted)